Palvella Therapeutics PVLA Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's change in AP?
- Palvella Therapeutics (PVLA) reported change in AP of $851K in Q1 2026.
- How has Palvella Therapeutics's change in AP changed year-over-year?
- Palvella Therapeutics's change in AP decreased by 24.3% year-over-year, from $1.12M to $851K.
- What is the long-term trend for Palvella Therapeutics's change in AP?
- Over 3 years (2021 to 2024), Palvella Therapeutics's change in AP has grown at a -31.8% compound annual growth rate (CAGR), from $7.05M to $2.24M.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.